A couple of days ago, we reported that the FDA has been “trying to figure out” why the Hepatitis C drug Sovaldi doesn’t work for the patients it was supposed to treat.

Well, a new report claims the agency is looking into the issue.

It’s not the first time the agency has looked into the drug.

According to a report from The Wall Street Journal, the FDA is also looking into Sovaldi’s efficacy for the elderly and children, as well as how the drug’s price is calculated.

“The FDA is currently reviewing the drug, and as of this writing, they have not found any indications of safety for the vast majority of patients,” the report said.

“But they are looking into a small number of indications of potential safety, and they are likely to be limited to certain patients, such as the elderly, children and people with diabetes.

So they have a good idea of what is out there, but they haven’t been able to verify that.”

In other words, the agency may be looking into whether the drug actually works as advertised.

The FDA is supposed to make the final decision about whether or not to approve Sovaldi, but it’s unclear whether that’s actually happening.

It could be a matter of a lot of testing, and the agency would have to make sure Sovaldi is safe before approving the drug for all people over age 65.

We’ll update this post if we hear anything more about the matter.